What is AceCann?
Founded in 2019, AceCann operates at the intersection of biotechnology and pharmaceutical manufacturing. The company distinguishes itself through a mission to provide consistent, high-quality products that facilitate access to life-changing medical innovations. By adhering to stringent pharmaceutical standards, AceCann addresses the critical need for reliability in the rapidly evolving medical cannabis market. Its strategic location in Portugal serves as a gateway for European distribution, allowing the firm to leverage regional expertise while maintaining a global outlook on patient health and longevity.
How much funding has AceCann raised?
AceCann has raised a total of $15M across 1 funding round:
Angel/Seed
$15M
Angel/Seed (2021): $15M with participation from Frank Cid, Marc Gare, Chris Mayle, Lince Capital, Casa Verde Capital, and Sebastian de la Rosa
Key Investors in AceCann
Casa Verde Capital
A premier venture capital firm dedicated exclusively to the cannabis industry, focusing on scalable businesses led by world-class management teams.
Lince Capital
A specialized financial solutions firm providing strategic capital and mercantile development support to emerging enterprises.
Frank Cid
An individual investor providing strategic backing to support the early-stage development and operational scaling of AceCann.
What's next for AceCann?
With this major enterprise-level funding, AceCann is poised to accelerate its operational footprint and deepen its research and development initiatives. The capital will likely be deployed to enhance manufacturing infrastructure, ensuring that the company meets the increasing demand for medical-grade cannabis products across international markets. As the regulatory environment for medical cannabis continues to mature, AceCann is well-positioned to capitalize on its early-mover advantage, focusing on scalable, capital-efficient growth strategies that align with the expectations of its institutional partners.
See full AceCann company page
